PMID: 9184630Jun 1, 1997Paper

Results of a phase I clinical trial of a T-cell receptor vaccine in patients with multiple sclerosis. II. Comparative analysis of TCR utilization in CSF T-cell populations before and after vaccination with a TCRV beta 6 CDR2 peptide

Journal of Neuroimmunology
D P GoldD B Wilson

Abstract

We report here the results of a phase I trial of a T-cell receptor (TCR) V beta 6 CDR2 region peptide vaccine in 10 patients with multiple sclerosis who showed biased over-representations of V beta 6 mRNA among T-cells in their cerebrospinal fluids (CSF). One group of 5 patients was immunized twice during a four week period with 100 micrograms of the TCRV beta 6 peptide 39-LGQGPEF LTYFQNEAQLEKS-58 emulsified in incomplete Freund's adjuvant (IFA); the second group of 5 MS patients received 300 micrograms of the same peptide in IFA over a similar time period. Patients were monitored for adverse events, immunogenicity of the peptide and changes in their CSF T-cell populations. The results indicate that this peptide was immunogenic (T-cell proliferation assays and recall DTH responses) in some of the patients, although none of the immunized patients produced detectable anti-peptide antibodies. More importantly, we show that the 5 patients treated with higher doses of the vaccine displayed a slight decrease in CSF cellularity, a lack of growth of CSF cells in cytokine supplemented expansion cultures that implies a significant absence of a subset of activated CD4 T-cells and a marked diminution in V beta 6 mRNA levels among T-cells i...Continue Reading

References

Feb 1, 1991·European Journal of Immunogenetics : Official Journal of the British Society for Histocompatibility and Immunogenetics·H ErlichP S Walsh
Jan 21, 1988·Nature·K E EllermanS W Brostoff
Feb 1, 1989·European Journal of Immunology·J ChlubaJ T Epplen
Mar 1, 1984·Proceedings of the Society for Experimental Biology and Medicine·B H Waksman, W E Reynolds
Mar 1, 1983·Annals of Neurology·C M PoserW W Tourtellotte
Aug 29, 1995·Proceedings of the National Academy of Sciences of the United States of America·J L CornetteC DeLisi

❮ Previous
Next ❯

Citations

Jul 2, 1999·Springer Seminars in Immunopathology·P Moss, J Bell
Jun 6, 2000·Advanced Drug Delivery Reviews·F C JensenJ C Chang
Nov 27, 1997·The New England Journal of Medicine·R A RudickR M Ransohoff
Oct 16, 1999·Journal of Neurology, Neurosurgery, and Psychiatry·R N HeardG J Stewart
Sep 25, 2002·Journal of the American Pharmaceutical Association : APhA·Melody Ryan, Peggy Piascik
Aug 13, 2004·Proceedings of the National Academy of Sciences of the United States of America·Reinhard Hohlfeld, Hartmut Wekerle
Dec 2, 2005·International Reviews of Immunology·Mireia Sospedra, Roland Martin
Dec 2, 2005·International Reviews of Immunology·Halina Offner, Arthur A Vandenbark
Jul 2, 2005·Expert Opinion on Investigational Drugs·E G Spack
Nov 3, 2004·The Journal of Clinical Investigation·Vipin Kumar
Jul 17, 1999·Multiple Sclerosis : Clinical and Laboratory Research·S Schmidt
Oct 8, 1998·Multiple Sclerosis : Clinical and Laboratory Research·P StinissenJ Raus
Feb 14, 2007·The Journal of International Medical Research·J ZhangL Si
Nov 1, 2008·Nature Reviews. Drug Discovery·Rocio S Lopez-Diego, Howard L Weiner
Mar 7, 2006·Biopolymers·Maria Claudia Alcaro, Anna Maria Papini
Oct 1, 2005·Multiple Sclerosis : Clinical and Laboratory Research·D N BourdetteA A Vandenbark
Jul 4, 2018·CNS Drugs·Floriana De AngelisJeremy Chataway
Dec 22, 2020·Frontiers in Pharmacology·Concetta Di NataleDaniela Marasco

❮ Previous
Next ❯

Related Concepts

Related Feeds

CSF & Lymphatic System

This feed focuses on Cerebral Spinal Fluid (CSF) and the lymphatic system. Discover the latest papers using imaging techniques to track CSF outflow into the lymphatic system in animal models.